Levomilnacipran (Fetzima)

@article{Saraceni2014Levomilnacipran,
  title={Levomilnacipran (Fetzima)},
  author={Megan M Saraceni and Jineane V. Venci and Mona A Gandhi},
  journal={Journal of Pharmacy Practice},
  year={2014},
  volume={27},
  pages={389 - 395}
}
In July 2013, the US Food and Drug Administration approved levomilnacipran extended release (ER; Fetzima), a serotonin-norepinephrine reuptake inhibitor, for the treatment of adults with major depressive disorder. Levomilnacipran is an active enantiomer of the racemic drug milnacipran that is currently approved in the United States for the treatment of fibromyalgia. This article provides an overview of the mechanism of action, pharmacokinetic properties, clinical efficacy, safety, and… 
7 Citations

Tables from this paper

Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder

Oral levomilnacipran extended-release ER was an effective and generally well-tolerated treatment in adults with MDD participating in 8-week phase III trials and a 1-year extension study and the efficacy was maintained during the extension study, with no new safety signals detected.

Novel and Investigational Drugs in Depression

This article will highlight new psychopharmacological agents and investigational directions which may show promise in achieving better outcomes and symptom relief for those suffering from depression.

New Antidepressant Medication: Benefits Versus Adverse Effects

The aim of this chapter is to review the literature, highlight the side effects of newer antidepressants, and especially point out the mostimportant aspectsofthelatestagentsapproved for treatment of major depressive disorder in adults: desvenlafaxine, levomilnacipran, vilazodone, and vortioxetine.

Characterization of a conglomerate-forming derivative of (±)-milnacipran and its enantiomeric resolution by preferential crystallization

Among some derivatives of milnacipran, a last-generation antidepressive drug with useful application in the treatment of fibromyalgia, N-isobutyramide (±)-4 was identified as a conglomerate-forming

Cu-catalysed transamidation of unactivated aliphatic amides.

A transamidation approach of an unactivated aliphatic amide is reported using a copper catalyst and chlorotrimethylsilane as an additive and used as a tool for selective N-C(O) cleavage and O-C (O) formation to synthesise 2-substituted benzoxazoles and benzothiazoles.

Assessment of Antidepressant Effect of the Aerial Parts of Micromeria myrtifolia Boiss. & Hohen on Mice

The present research confirmed the antidepressant’s potential of Micromeria myrtifolia Boiss by evaluating the antidepressant activity of the extracts evaluated by using several in vivo and in vitro experimental models of depression.

References

SHOWING 1-10 OF 33 REFERENCES

Efficacy and tolerability of milnacipran: an overview

It is suggested that milnacipran offers clinical advantages over TCAs in terms of tolerability, and over SSRIs in termsOf efficacy, and in particular, the lack of cardiovascular adverse events appears to offer advantages in cases of deliberate overdose.

Milnacipran: a unique antidepressant?

  • S. KasperG. Pail
  • Medicine, Psychology
    Neuropsychiatric disease and treatment
  • 2010
Clinical studies have shown that milnacipran has efficacy comparable with the TCAs and is superior to SSRIs in severe depression, and it is frequently successful when other treatments fail for reasons of efficacy or tolerability.

Milnacipran and selective serotonin reuptake inhibitors in major depression

Clinical trials comparing the new SNRI milnacipran with the SSRIs fluoxetine and fluvoxamine suggest that milnadrenaline reuptake inhibitors is superior in efficacy to SSRI and is equally well tolerated, and milnACipran, therefore, appears to offer a therapeutic advantage over theSSRIs.

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results

Milnacipran is as effective as TCAs in the treatment of patients with major depression and is better tolerated, and its lack of effects on cardiovascular function offers improved safety in cases of overdose.

Clinical efficacy of milnacipran: placebo‐controlled trials

A subgroup analysis of hospitalized patients in the meta-analysis showed an advantage for milnacipran, suggesting that milnadrenaline reuptake inhibitor is effective in more severe depression.

SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants

Abstract The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of both

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

The commonly used criteria of treatment effect and responder rates, as well as the percentage difference in responders between antidepressant and placebo, are critically reviewed and applied to assess the clinical relevance of the significant advantages reported in double-blind, randomized, controlled studies of escitalopram compared with other antidepressants.

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

Levomilnacipran SR demonstrated robust efficacy on all measures and was generally well tolerated in major depressive disorder and in outpatients meeting DSM-IV criteria for a major depressive episode.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Levomilnacipran SR demonstrated significant improvement in depressive symptoms and functioning relative to placebo in patients with major depressive disorder and was generally well tolerated.